文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

静脉扎那米韦与口服奥司他韦治疗住院流感患者:一项国际、随机、双盲、双模拟、3期试验

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2017-01-14
一句话结论在住院重症流感患者中,静脉扎那米韦600mg每日两次的临床应答时间不优于口服奥司他韦75mg每日两次或静脉扎那米韦300mg每日两次。

这项国际、随机、双盲、双模拟、3期试验纳入626例16岁及以上重症流感住院患者,随机接受静脉扎那米韦300mg、600mg或口服奥司他韦75mg每日两次,疗程5-10天,随访28天。488例(78%)实验室确诊流感。600mg静脉扎那米韦组中位临床应答时间5.14天,300mg组5.87天(差值-0.73天,95%CI -1.79至0.75;P=0.25),奥司他韦组5.63天(差值-0.48天,95%CI -2.11至0.97;P=0.39),均无统计学显著差异。奥司他韦组4例甲型H1N1pdm09流感患者出现H275Y耐药突变。不良事件各组相似,最常见为腹泻、呼吸衰竭和便秘。作者结论:600mg静脉扎那米韦的临床应答时间不优于奥司他韦或300mg静脉扎那米韦,所有治疗安全性相似。

要点

  • 在488例实验室确诊流感的住院患者中,600mg静脉扎那米韦组中位临床应答时间5.14天,300mg组5.87天,奥司他韦组5.63天,差异均未达统计学显著。
  • 600mg静脉扎那米韦与奥司他韦比较,中位临床应答时间差值-0.48天(95%CI -2.11至0.97;P=0.39),未达到预设的1.5天改善。
  • 600mg静脉扎那米韦与300mg静脉扎那米韦比较,差值-0.73天(95%CI -1.79至0.75;P=0.25),同样无显著差异。
  • 奥司他韦组4例甲型H1N1pdm09流感患者出现H275Y耐药突变。
  • 不良事件发生率各组相似(总61%),最常见为腹泻、呼吸衰竭和便秘;治疗患者中41例(7%)死亡,最常见死因为呼吸衰竭和脓毒性休克。

适用人群与场景

  • 年龄16岁及以上、因重症流感住院的患者,来自26个国家97家医院。
  • 随机分层因素为症状出现至入组时间≤4天或5-6天。

处置流程与药物剂量

  • 静脉扎那米韦300mg,每日两次,疗程5-10天。
  • 静脉扎那米韦600mg,每日两次,疗程5-10天。
  • 口服奥司他韦75mg,每日两次,疗程5-10天(标准治疗对照)。
  • 随访28天。

研究设计与关键结果

  • 研究类型:国际、随机、双盲、双模拟、3期试验;样本量626例随机(300mg组201例,600mg组209例,奥司他韦组205例),97家医院,26个国家;488例(78%)实验室确诊流感。
  • 主要终点:流感阳性人群的临床应答时间(生命体征稳定与出院的复合终点)。600mg静脉扎那米韦组中位5.14天;300mg组5.87天(差值-0.73天,95%CI -1.79至0.75;P=0.25);奥司他韦组5.63天(差值-0.48天,95%CI -2.11至0.97;P=0.39),均未达统计学显著。
  • 耐药:奥司他韦组4例甲型H1N1pdm09流感患者出现H275Y耐药突变。
  • 安全性:治疗患者中373例(61%)报告不良事件,各组相似;最常见不良事件(300mg静脉扎那米韦、600mg静脉扎那米韦、奥司他韦)为腹泻(10例[5%]、15例[7%]、14例[7%])、呼吸衰竭(11例[5%]、14例[7%]、11例[5%])、便秘(7例[3%]、13例[6%]、10例[5%])。
  • 死亡:治疗患者中41例(7%)死亡(300mg组15例[7%],600mg组15例[7%],奥司他韦组11例[5%]);最常见死因为呼吸衰竭和脓毒性休克。

证据类型、等级与局限

  • 证据类型:国际、随机、双盲、双模拟、3期试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,600mg静脉扎那米韦的临床应答时间不优于奥司他韦或300mg静脉扎那米韦;所有治疗在住院重症流感患者中安全性相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous zanamivir was a suitable treatment in this setting.

METHODS: In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to 97 hospitals from 26 countries. We randomly assigned patients (1:1:1 stratified by symptom onset ≤4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients were followed up for 28 days. The randomisation schedule, including stratification, was generated using GlaxoSmithKline's RandAll software. Patients, site study staff, and sponsor were masked to study treatment. The primary endpoint was time to clinical response-a composite of vital sign stabilisation and hospital discharge-in the influenza-positive population. The trial was powered to show an improvement of 1·5 days or greater with 600 mg intravenous zanamivir. Pharmacokinetic, safety, and virology endpoints were also assessed. This trial is registered with ClinicalTrials.gov, number NCT01231620.

FINDINGS: Between Jan 15, 2011, and Feb 12, 2015, 626 patients were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatment. 488 (78%) of 626 patients had laboratory-confirmed influenza. Compared with a median time to clinical response of 5·14 days in the 600 mg intravenous zanamivir group, the median time to clinical response was 5·87 days (difference of -0·73 days, 95% CI -1·79 to 0·75; p=0·25) in the 300 mg intravenous zanamivir group and 5·63 days (difference of -0·48 days, 95% CI -2·11 to 0·97; p=0·39) in the oseltamivir group. Four patients with influenza A/H1N1pdm09 in the oseltamivir group developed H275Y resistance mutations. Adverse events were reported in 373 (61%) of treated patients and were similar across treatment groups; the most common adverse events (300 mg intravenous zanamivir, 600 mg intravenous zanamivir, oseltamivir) were diarrhoea (10 [5%], 15 [7%], 14 [7%]), respiratory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]). 41 (7%) treated patients died during the study (15 [7%], 15 [7%], 11 [5%]); the most common causes of death were respiratory failure and septic shock.

INTERPRETATION: Time to clinical response to intravenous zanamivir dosed at 600 mg was not superior to oseltamivir or 300 mg intravenous zanamivir. All treatments had a similar safety profile in hospitalised patients with severe influenza.

FUNDING: GlaxoSmithKline.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017. PMID: 28094141. doi:10.1016/S2213-2600(16)30435-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。